Skip to content

Study · Case report or series · n = 1 · 2021

1 result

A Rare Case of Dulaglutide-Associated Angioedema in a Male Patient.

Karakousis N, Kostakopoulos NA, Georgakopoulou VE, Pyrgioti EE, Georgakopoulos PN

Cureus30 Nov 2021Cited by 6 (Europe PMC)

PMID34987924 (opens in a new tab)PMCIDPMC8717822 (opens in a new tab)DOI10.7759/cureus.20041 (opens in a new tab)PepBankPUB-34987924
Download PDFPubMedAsk about this study
Jump to 1 result

Summary

Dulaglutide is an injectable glucagon-like peptide-1 receptor agonist approved for the treatment of adults with type 2 diabetes. Angioedema is defined as self-limiting edema, localized in the deeper layers of the skin and mucosa. Angioedema can be hereditary or acquired which can be allergic due to reactions to foods, insect bites and stings, and latex, drug-induced, caused by physical stimuli and associated with lupus erythematosus and hypereosinophilia. Angioedema represents a rare adverse event of glucagon-like peptide-1 receptor agonists. The only glucagon-like peptide-1 receptor agonist that has been mentioned to induce angioedema in literature is exenatide. We report the first case of dulaglutide-associated angioedema in a 72-year-old male in order to point out to the clinicians this potential rare side effect of this drug and its clinical significance.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study1

1 result from studies that gave the peptide. 1 result from people.

  1. 01HumanCase report or seriesSafety outcome

    In a male patient, angioedema was associated with dulaglutide.

    In plain wordsA male patient developed angioedema associated with dulaglutide.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    Not applicableAngioedema
    Study

    n = 1

    Outcome group
    Adverse events · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    We report the first case of dulaglutide-associated angioedema in a 72-year-old male in order to point out to the clinicians this potential rare side effect of this drug and its clinical significance.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:25 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.